Theravance Biopharma, Inc. (TBPH) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
3.58
↓-11% vs avg
5yr avg: 4.04
30Y Low4.0·High4.0
P/B Ratio
↑
2.87
+8% vs avg
5yr avg: 2.66
30Y Low1.6·High12.7
ROE
↓
44.8%
↑-89% vs avg
5yr avg: 422.2%
30Y Low-174%·High45%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TBPH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Theravance Biopharma, Inc. trades at 8.0x earnings, 11% below its 5-year average of 9.1x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 64%. On a free-cash-flow basis, the stock trades at 3.6x P/FCF, 11% below the 5-year average of 4.0x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $854M | $964M | $460M | $622M | $826M | $768M | $1.1B | $1.4B | $1.4B | $1.5B | $1.4B |
| Enterprise Value | $761M | $871M | $472M | $631M | $580M | $1.3B | $1.7B | $1.9B | $1.5B | $1.6B | $1.3B |
| P/E Ratio → | 8.04 | 9.08 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 7.94 | 8.97 | 7.14 | 10.82 | 16.08 | 13.88 | 15.42 | 19.61 | 22.88 | 94.90 | 29.30 |
| P/B Ratio | 2.87 | 3.25 | 2.62 | 2.92 | 1.87 | — | — | — | — | 12.68 | 4.07 |
| P/FCF | 3.58 | 4.04 | — | — | — | — | — | — | — | — | — |
| P/OCF | 3.58 | 4.04 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TBPH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.11 | 7.33 | 10.99 | 11.29 | 24.36 | 23.70 | 25.77 | 24.14 | 103.66 | 26.79 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 3.65 | — | — | — | — | — | — | — | — | — |
TBPH Profitability
Margins and return-on-capital ratios measuring operating efficiency
Theravance Biopharma, Inc. earns an operating margin of -12.3%. Operating margins have expanded from -97.6% to -12.3% over the past 3 years, signaling improving operational efficiency. Return on equity of 44.8% is exceptionally high.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.9% | 94.9% | 100.0% | 29.3% | -23.5% | -250.1% | 100.0% | 100.0% | 98.8% | 60.8% | 94.1% |
| Operating Margin | -12.3% | -12.3% | -72.9% | -97.6% | -179.1% | -466.1% | -414.2% | -343.1% | -395.5% | -1690.6% | -371.0% |
| Net Profit Margin | 98.5% | 98.5% | -87.6% | -96.1% | 1698.5% | -360.6% | -386.9% | -322.1% | -357.0% | -1855.0% | -391.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 44.8% | 44.8% | -29.0% | -16.9% | 1689.7% | — | — | — | -677.9% | -122.6% | -64.3% |
| ROA | 25.2% | 25.2% | -15.3% | -11.2% | 177.6% | -47.3% | -63.3% | -48.8% | -43.0% | -52.8% | -40.6% |
| ROIC | -5.1% | -5.1% | -17.2% | -20.1% | -31.6% | -72.7% | -85.9% | -149.1% | -130.4% | -81.6% | -75.5% |
| ROCE | -3.4% | -3.4% | -13.8% | -12.0% | -20.6% | -77.9% | -92.6% | -66.4% | -56.8% | -53.7% | -42.9% |
TBPH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $168M exceeds total debt of $75M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.25 | 0.25 | 0.28 | 0.23 | 0.12 | — | — | — | — | 1.94 | 0.64 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.31 | 0.07 | 0.05 | -0.56 | — | — | — | — | 1.17 | -0.35 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.39 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -5.38 | -5.38 | -16.52 | -22.83 | -12.42 | -27.80 | -34.49 | -6.59 | -20.57 | -30.79 | -127.60 |
Net cash position: cash ($168M) exceeds total debt ($75M)
TBPH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Theravance Biopharma, Inc.'s current ratio of 10.93x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.39x to 10.93x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.93 | 10.93 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 | 3.03 | 5.41 | 6.05 | 10.73 |
| Quick Ratio | 10.93 | 10.93 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 | 3.03 | 5.41 | 5.79 | 10.48 |
| Cash Ratio | 8.23 | 8.23 | 2.75 | 4.14 | 11.40 | 2.96 | 2.37 | 2.51 | 5.13 | 5.57 | 10.17 |
| Asset Turnover | — | 0.22 | 0.18 | 0.15 | 0.08 | 0.15 | 0.15 | 0.18 | 0.11 | 0.03 | 0.08 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 0.36 | 0.24 |
| Days Sales Outstanding | — | 324.50 | 388.01 | 111.07 | 119.32 | 380.10 | 353.88 | 251.42 | 64.53 | 222.09 | 72.94 |
TBPH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Theravance Biopharma, Inc. returns 0.5% to shareholders annually primarily through share buybacks. The earnings yield of 12.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 12.4% | 11.0% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 27.9% | 24.7% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.5% | 0.4% | 0.7% | 32.1% | 16.0% | 1.2% | 0.9% | 0.2% | 0.7% | 0.6% | 0.3% |
| Total Shareholder Yield | 0.5% | 0.4% | 0.7% | 32.1% | 16.0% | 1.2% | 0.9% | 0.2% | 0.7% | 0.6% | 0.3% |
| Shares Outstanding | — | $52M | $49M | $55M | $74M | $69M | $62M | $56M | $54M | $52M | $45M |
Peer Comparison
Compare TBPH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TBPHYou | $854M | 8.0 | — | 3.6 | 94.9% | -12.3% | 44.8% | -5.1% | — |
 INVA | $2B | 6.9 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRGO | $1B | -0.9 | 7.0 | 9.2 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 SUPN | $3B | -65.4 | 45.2 | 55.7 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PCRX | $893M | 141.9 | 9.6 | 6.5 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 INSM | $21B | -15.4 | — | — | 79.4% | -194.0% | -249.3% | -86.5% | — |
 ARWR | $12B | -6721.3 | 95.6 | 73.6 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 TPVG | $193M | 3.9 | 8.5 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 NKTR | $1B | -6.8 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 GSK | $102B | 6.9 | 8.6 | 13.3 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
 JNJ | $557B | 39.9 | 19.3 | 28.1 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
TBPH — Frequently Asked Questions
Quick answers to the most common questions about buying TBPH stock.
What is Theravance Biopharma, Inc.'s P/E ratio?
Theravance Biopharma, Inc.'s current P/E ratio is 8.0x. The historical average is 9.1x.
What is Theravance Biopharma, Inc.'s ROE?
Theravance Biopharma, Inc.'s return on equity (ROE) is 44.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -61.5%.
Is TBPH stock overvalued?
Based on historical data, Theravance Biopharma, Inc. is trading at a P/E of 8.0x. Compare with industry peers and growth rates for a complete picture.
What are Theravance Biopharma, Inc.'s profit margins?
Theravance Biopharma, Inc. has 94.9% gross margin and -12.3% operating margin.